期刊
DRUG TESTING AND ANALYSIS
卷 7, 期 9, 页码 737-744出版社
WILEY
DOI: 10.1002/dta.1824
关键词
platinum; breast cancer; pharmacokinetics; benzene-poly-carboxylic acids; inductively coupled plasma mass spectrometry
资金
- collaborative research group at the N.N. Petrov Research Institute of Oncology
- Meabco A/S
A method of platinum quantification in whole blood samples after microwave digestion using sector field inductively coupled plasma mass spectrometry has been developed. The following analytical figures of merit have been established: limit of detection 1.1 mu g/L for blood samples, dynamic range 3.6-200 mu g/L, intra-day precision (relative standard deviation, n = 9) did not exceed 5%. Spiked samples were analyzed for method validation. The method was used for pharmacokinetics studies of a novel anti-cancer drug BP-C1, a complex of cis-configured platinum and benzene-poly-carboxylic acids. Main pharmacokinetic parameters (area under curve, maximum concentration, clearance, half-life times for - and -phase) were estimated for two dosage forms of BP-C1 0.05 and 0.125 mass %. Pharmacokinetic curves were assessed for single and course administration. Studies were performed using rabbits (n = 6) as a model. BP-C1 was injected intramuscularly. The study established dose proportionality of the tested dosage forms and suggested clinical dosing schedule: 5 days of injections followed by 2 days' break. Platinum tissue distribution was studied in tissue samples collected 20 days after the last injection. Predominant platinum accumulation was observed in kidneys, liver, and muscles near injection site. Slow' phase of platinum excretion kinetics may be related to the muscles at the injection site. (c) 2015 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据